Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: This article which all of you have read is but 4 months old , a little time has

< I read this as saying PTSC and shareholders will get substantially less from future licensing proceeds because TPL will get substantially more working capital from these proceeds. Is there another way to read this?.">

Correct if the pie stays the same or gets smaller. If the size of the pie increases substantially, we get more.

Opty

Share
New Message
Please login to post a reply